Lenvatinib
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Unresectable Hepatocellular Carcinoma (HCC)
Conditions
Unresectable Hepatocellular Carcinoma (HCC)
Trial Timeline
Sep 1, 2016 → Dec 28, 2020
NCT ID
NCT02953743About Lenvatinib
Lenvatinib is a phase 1 stage product being developed by Eisai for Unresectable Hepatocellular Carcinoma (HCC). The current trial status is completed. This product is registered under clinical trial identifier NCT02953743. Target conditions include Unresectable Hepatocellular Carcinoma (HCC).
What happened to similar drugs?
1 of 20 similar drugs in Unresectable Hepatocellular Carcinoma (HCC) were approved
Approved (1) Terminated (1) Active (18)
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03533361 | Pre-clinical | Completed |
| NCT02211222 | Pre-clinical | Completed |
| NCT05901194 | Phase 1/2 | Active |
| NCT06138769 | Phase 2 | Active |
| NCT05171335 | Phase 2 | Recruiting |
| NCT05103904 | Phase 2 | Recruiting |
| NCT04321954 | Phase 2 | Active |
| NCT04297254 | Approved | Completed |
| NCT04447755 | Phase 2 | Completed |
| NCT04008082 | Pre-clinical | Completed |
| NCT03506048 | Phase 2 | Terminated |
| NCT03009292 | Phase 1 | Completed |
| NCT03663114 | Pre-clinical | Completed |
| NCT02846766 | Phase 2 | Withdrawn |
| NCT03433703 | Phase 2 | Terminated |
| NCT03573960 | Approved | Completed |
| NCT03168074 | Phase 2 | UNKNOWN |
| NCT02953743 | Phase 1 | Completed |
| NCT02780310 | Phase 2 | Active |
| NCT02579616 | Phase 2 | Completed |
Competing Products
20 competing products in Unresectable Hepatocellular Carcinoma (HCC)